Skip to content

Now investing: Join the movement. Aspivix is open for crowdfunding. Invest Now →

Aspivix logo
  • News
  • About us
  • Contact
  • Distribution Network
  • English
    • Français
    • Italiano
    • Deutsch
Buy Now
Search
Close
  • For Healthcare Professionals
  • For Women
  • Find your OBGYN
  • Resources
  • News
  • About us
  • Contact
  • Distribution Network
  • English
    • Français
    • Italiano
    • Deutsch
Buy Now
  • For Healthcare Professionals
  • For Women
  • Find your OBGYN
  • Resources
Aspivix logo
Home > News

Press Contact
For media enquiries, please reach out to: contact@aspivix.com

All
  • All
  • Blog
  • In the media
  • Press releases
35

More than 40% of Pregnancies Globally are Unintended

June 20, 2020
Worldwide, about 85 million annual pregnancies are unintended, or >40% of all pregnancies. These pregnancies result in 50%  abortions, 12% miscarriages, and 38% unplanned births. The impact is substantial costs to healthcare...
Read More about More than 40% of Pregnancies Globally are Unintended
84

ASPIVIX Empowers Women Around the Globe

February 21, 2020
Read More about ASPIVIX Empowers Women Around the Globe
85

7 European femtech startups taking women’s health into the future

February 4, 2020
Read More about 7 European femtech startups taking women’s health into the future
86

16 companies join Innosuisse’s first scale-up programme

January 13, 2020
Read More about 16 companies join Innosuisse’s first scale-up programme
87

Replacing a Centuries-Old Gynecological Instrument

December 8, 2019
Read More about Replacing a Centuries-Old Gynecological Instrument
88

ASPIVIX in Venture Kick final

November 11, 2019
Read More about ASPIVIX in Venture Kick final
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
Loading... loader
Scroll to learn more

Company

  • Home

Contact

Global Headquarters
Aspivix SA
Route de la Corniche 8
1066 Epalinges
Switzerland

contact@aspivix.com

Legal

  • Cookie Policy
  • Privacy Statement
  • Imprint
  • Disclaimer

Follow

Carevix® is currently FDA-Cleared for US market, CE-Marked for EU market and authorized in UK and Brazil. Available for commercialization. It has not been licensed or approved for sale in other markets.

© 2026 Aspivix SA. All rights reserved. Aspivix™, and Carevix® are trademarks or registered trademarks of Aspivix SA and/or its subsidiaries.

Where are you located?

Europe
United States

Where are you located?

Europe
United States